Cargando…
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy
INTRODUCTION: Immune checkpoint inhibitors (ICIs), particularly anti-PD-1 antibody, have dramatically changed cancer treatment; however, fatal immune-related adverse events (irAEs) can develop. Here, we describe a severe case of sclerosing cholangitis-like irAE. We report the use of 3 immunosuppress...
Autores principales: | Hirasawa, Yuya, Yoshimura, Kiyoshi, Matsui, Hiroto, Kubota, Yutaro, Ishida, Hiroo, Arai, Jun, Sakaki, Masashi, Oguro, Nao, Shida, Midori, Taniguchi, Makoto, Hamada, Kazuyuki, Ariizumi, Hirotsugu, Ishiguro, Tomoyuki, Ohkuma, Ryotaro, Sambe, Takehiko, Horiike, Atsushi, Imamura, Chiyo K., Shiozawa, Eisuke, Wada, Satoshi, Tsurutani, Junji, Iwamoto, Sanju, Uchida, Naoki, Kiuchi, Yuji, Tate, Genshu, Kobayashi, Shinichi, Tsunoda, Takuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202549/ https://www.ncbi.nlm.nih.gov/pubmed/34114983 http://dx.doi.org/10.1097/MD.0000000000025774 |
Ejemplares similares
-
A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report
por: Hamada, Kazuyuki, et al.
Publicado: (2022) -
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies
por: Ohkuma, Ryotaro, et al.
Publicado: (2021) -
Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
por: Hamada, Kazuyuki, et al.
Publicado: (2023) -
High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer
por: Ohkuma, Ryotaro, et al.
Publicado: (2020) -
High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer
por: Ohkuma, Ryotaro, et al.
Publicado: (2020)